4.7 Article

Generation and Characterization of a Spike Glycoprotein Domain A-Specific Neutralizing Single-Chain Variable Fragment against Porcine Epidemic Diarrhea Virus

Journal

VACCINES
Volume 9, Issue 8, Pages -

Publisher

MDPI
DOI: 10.3390/vaccines9080833

Keywords

porcine epidemic diarrhea virus; single-chain variable fragment (scFv); neutralizing antibody

Funding

  1. Academia Sinica intramural fund
  2. Academia Sinica Career Development Award, Academia Sinica [AS-CDA-109-L08]
  3. Ministry of Science and Technology (MOST), Taiwan [MOST 109-3114-Y-001001, MOST106-2311-B-002-028-MY3]

Ask authors/readers for more resources

The emergence of the G2 genotype and re-emergence of G1 porcine epidemic diarrhea virus have caused severe economic impacts, and the development of new variant vaccines has been challenging. The scFv specific to G2b PEDV could potentially be used as a therapeutic candidate against the virulent PEDV.
The emergence of the genotype (G) 2 and re-emergence of the G1 porcine epidemic diarrhea virus (PEDV) has caused severe economic impacts in the past decade. Developments of efficient vaccines against new variants of PEDV have been challenging, not least because of the difficulties in eliciting mucosal and lactogenic immunity. A single-chain fragment variable (scFv) capable of efficient antigen recognition is an alternative to vaccination and treatment of a viral infection. In the present study, the variable regions of the light chain and the heavy chain of a G2b PEDV spike domain A (S1(A))-specific neutralizing monoclonal antibody (mAb) were sequenced, constructed with a (G4S) x3 linker, and produced by a mammalian protein expression system. Our results demonstrated that the PEDV S1(A) domain scFv was able to bind to S proteins of both G1 and G2b PEDVs. Nevertheless, the scFv was only capable of neutralizing the homologous G2b PEDV but not the G1 PEDV. The binding ability of the G2b-specific neutralizing scFv was not able to predict the neutralizing ability toward heterologous PEDV. The anti-PEDV S1(A) scFv presented herein serves as a potential therapeutic candidate against the virulent G2b PEDV.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available